title: Impact of progestagens on activated protein C (APC) resistance among users of oral contraceptives.
abstract: Oral contraceptive (OC) use is associated with an increased risk of venous thromboembolism. Previous data reported higher thrombotic risk in women using third-generation combined OC than in those using second generation OC. The difference could be explained by differential effects of progestagens on plasma sensitivity to activated protein C (APC). The main purpose of this cross-sectional study was to assess the influence of a progestagen-only OC (chlormadinone acetate) as well as the effect of several combined OC with different progestagen components on APC resistance. The effect of APC on endogenous thrombin potential (ETP) was investigated in the plasma of healthy women using either combined OC (n=82) or progestagen-only OC (n=28), and in non-users (n=64). Carriers of factor V Leiden were excluded. Compared with non-users, there was no significant change in APC resistance in women using progestagen-only OC. Women who used combined OC were less sensitive to APC than non-users (P < 0.001) and the difference was significantly more pronounced in women using third-generation OC (n=41) than in those who used second-generation OC containing levonorgestrel (n=22) (P < 0.05). Compared with OC containing levonorgestrel, use of norethisterone-containing OC (n = 9) was associated with an increased resistance to APC (P < 0.05). Women who used cyproterone-containing OC (n = 10) were less sensitive to APC than those using third-generation OC (P < 0.05) or second-generation OC containing levonorgestrel (P < 0.05). Protein S, factor II and FVIII levels explained in part the OC-related changes in APC sensitivity variations. ETP-based APC resistance may contribute to explain why different brands of OC can be associated with different levels of thrombogenicity.
authors.affiliation: Service d'Hématologie Biologique A, Hôpital Européen Georges Pompidou (AP-HP), Paris.
authors.forename: M
authors.initials: M
authors.lastname: Alhenc-Gelas
authors.forename: G
authors.initials: G
authors.lastname: Plu-Bureau
authors.forename: S
authors.initials: S
authors.lastname: Guillonneau
authors.forename: J-M
authors.initials: JM
authors.lastname: Kirzin
authors.forename: M
authors.initials: M
authors.lastname: Aiach
authors.forename: N
authors.initials: N
authors.lastname: Ochat
authors.forename: P-Y
authors.initials: PY
authors.lastname: Scarabin
mesh_terms: D020016:Activated Protein C Resistance / Q000097:blood / Q000139:chemically induced*; D000328:Adult; D002715:Chlormadinone Acetate / Q000009:adverse effects; D003276:Contraceptives, Oral / Q000009:adverse effects*; D003277:Contraceptives, Oral, Combined / Q000009:adverse effects; D003280:Contraceptives, Oral, Synthetic / Q000009:adverse effects; D003430:Cross-Sectional Studies; D015914:Estrogen Replacement Therapy / Q000009:adverse effects; D005260:Female; D006801:Humans; D008875:Middle Aged; D045167:Progesterone Congeners / Q000009:adverse effects*; D013923:Thromboembolism / Q000139:chemically induced; D020246:Venous Thrombosis / Q000139:chemically induced
chemical_list: D003276:Contraceptives, Oral; D003277:Contraceptives, Oral, Combined; D003280:Contraceptives, Oral, Synthetic; D045167:Progesterone Congeners; D002715:Chlormadinone Acetate